In ICC models characterized by exceptionally poor responses to immune checkpoint inhibitors, dual inhibition of METTL1 and its downstream chemokine signaling substantially enhances anti-PD-1 efficacy, representing a promising immunotherapeutic strategy [188]. This evidence concerns the gene METTL1 and intrahepatic cholangiocarcinoma.